iPamorelin is a GHRP (Growth Hormone Releasing Peptide) that is considered one of the mildest due to it being perhaps the most side effect friendly of the GHRP hormones. iPamorelin was first developed by Novo Nordisk and made its way to phase two clinical trials through Helsinn Therapeutics. However, while it showed promising results the full trials were never completed and the project was scrapped. Although it is not found in medical circles it is used in some performance based circles in lieu of Human Growth Hormone (HGH).
iPamorelin Functions and Traits
iPamorelin is very similar to GHRP-6 in that it increases ghrelin and targets a specific GH pulse. However, unlike GHRP-6 there doesn’t appear to be an increase in hunger that often exists with GHRP-6. More importantly, there is no impact on cortisol and only on plasma Growth Hormone (GH) levels. Unlike many other GH peptides such as Hexarelin, there doesn’t appear to be a strong breach of desensitization. This means there is no point where a dose doesn’t improve natural GH secretion.
Along with powerful GH releasing abilities, iPamorelin is also one of the longest lasting GH peptides available. The release of the hormone (GH) isn’t an instant spike followed by a rapid falloff point but instead a slow steady release that is more natural to the body.
